Sign in to continue:

Saturday, July 25th, 2026

Corrigendum to Chemical Industries (Far East) Limited Annual Report 2026 – Profile of Founder Lim Soo Peng

Chemical Industries (Far East) Limited Issues Corrigendum to Annual Report FY2026

Chemical Industries (Far East) Limited Issues Corrigendum to Annual Report FY2026

Key Points for Investors

  • Corrigendum Released: The company has issued a formal corrigendum to its Annual Report for the financial year ended 31 March 2026.
  • Additional Pages Inserted: Shareholders are informed that two new pages—24A (blank) and 24B (profile of Mr Lim Soo Peng)—are to be inserted immediately after page 24 and before page 25 in the Annual Report.
  • Profile of Founder Added: The profile of Mr Lim Soo Peng, Founder, Emeritus Chairman, and Senior Adviser, is now officially included in the Annual Report.
  • No Other Changes: All other information in the Annual Report remains unchanged.

Details of the Corrigendum and Mr Lim Soo Peng’s Profile

Background

The Board of Directors of Chemical Industries (Far East) Limited has notified shareholders of an important update to the Annual Report for FY2026. This update ensures transparency and completeness in the company’s reporting, which is critical for informed investment decisions.

Key Additions

The corrigendum introduces two pages:

  • Page 24A: This page is intentionally left blank and does not contain any material information.
  • Page 24B: This page provides a detailed profile of Mr Lim Soo Peng, who is a significant figure in the company’s history and governance.

Profile of Mr Lim Soo Peng

  • Founder and Emeritus Chairman: Mr Lim founded the company in 1962 in response to the Singapore Government’s industrialisation initiative.
  • Leadership Evolution: Under his stewardship, Chemical Industries (Far East) evolved from a commodities trading house to a manufacturer and supplier of essential chemicals.
  • Board Tenure: Mr Lim served in various executive and non-executive capacities for over six decades:
    • Chairman and Managing Director: 16 March 1962 to 13 August 2020
    • Managing Director and Executive Director: 14 August 2020 to 30 September 2021
    • Executive Director: 1 October 2021 to 31 December 2021
    • Non-Executive Director: 1 January 2022 to 28 July 2022
    • Emeritus Chairman, Non-Executive and Non-Independent Director: 28 July 2022 to 18 July 2025
  • Post-Retirement Role: After retiring from the Board on 18 July 2025, Mr Lim continues as Founder and Emeritus Chairman, serving as Senior Adviser. He provides industry and institutional knowledge to the Board and Management upon request but does not participate in formal board decisions.
  • National and Community Service:
    • Justice of the Peace since 1966
    • Member of Parliament in Singapore’s First and Second Parliaments (1965-1972)
    • Served on various government committees and statutory boards for over four decades
    • Recipient of multiple public service awards:
      • The Public Service Medal (1977)
      • The Public Service Star (2001)
      • The Public Service Star (Bar, 2014)
    • SG50 Outstanding Chinese Business Pioneers Award (2015)

Potential Price Sensitivity and Shareholder Implications

Investor Impact: The insertion of Mr Lim’s profile into the Annual Report may have indirect implications for shareholders. Mr Lim’s legacy and continued advisory role underscore the company’s commitment to stability, seasoned leadership, and continuity. While there are no immediate operational or financial changes disclosed, the reaffirmation of Mr Lim’s ongoing influence as Senior Adviser may bolster investor confidence, particularly in relation to succession planning and strategic direction.

Price Sensitivity: There is no direct price-sensitive information disclosed in this corrigendum. The update is primarily an enhancement of the Annual Report’s completeness and transparency regarding corporate governance.

Important Notes for Shareholders

  • The Annual Report for FY2026 should be read in conjunction with this corrigendum and the newly inserted pages.
  • Shareholders should note that the company’s leadership and advisory structure remains robust, with Mr Lim’s expertise accessible to management.
  • No changes to financial results, operations, or other material disclosures have been announced.

Conclusion

The corrigendum strengthens the transparency and completeness of the company’s Annual Report, highlighting the enduring influence of its founder. Investors should be aware of Mr Lim’s advisory role, which may reinforce confidence in the company’s governance but does not constitute a direct price-sensitive event.

Disclaimer

The information provided in this article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions.


化学工业(远东)有限公司发布2026财年年度报告更正通知

投资者重点信息

  • 更正通知发布:公司针对截至2026年3月31日的年度报告发布了正式更正通知。
  • 新增页面:股东需注意,年度报告中插入了两页——24A(空白)和24B(林树平先生个人简介),插入位置为第24页后、第25页前。
  • 创始人简介:林树平先生作为创始人、名誉主席及高级顾问,其个人简介已正式纳入年度报告。
  • 其他信息无变动:年度报告其他内容未作更改。

更正内容及林树平先生简介

  • 创始人及名誉主席:林树平先生于1962年响应新加坡政府工业化号召创办公司。
  • 领导历程:在其领导下,公司从大宗商品贸易商转型为必需化学品制造商与供应商。
  • 董事会任期:林先生在董事会六十余年,历任多项职务:
    • 董事长兼董事总经理:1962年3月16日—2020年8月13日
    • 董事总经理兼执行董事:2020年8月14日—2021年9月30日
    • 执行董事:2021年10月1日—2021年12月31日
    • 非执行董事:2022年1月1日—2022年7月28日
    • 名誉主席、非执行及非独立董事:2022年7月28日—2025年7月18日
  • 退休后角色:2025年7月18日退休后,林先生继续担任公司创始人及名誉主席,同时作为高级顾问,为董事会和管理层提供行业和机构知识(按需),但不参与董事会正式决策。
  • 社会和公共服务:
    • 1966年起担任和平法官
    • 1965-1972年为新加坡第一、二届国会议员
    • 四十余年服务于政府委员会与法定机构
    • 获多项公共服务奖:
      • 1977年公共服务奖章
      • 2001年公共服务星章
      • 2014年公共服务星章(加章)
    • 2015年获新加坡中华总商会“SG50杰出华商先锋奖”

对股东和股价的潜在影响

虽然本次更正未披露直接影响公司运营或财务的重大信息,但林先生持续担任高级顾问,表明公司治理稳健、领导层经验丰富,有助于投资者信心提升,尤其在董事会继任及战略方向方面。但该信息并非直接价格敏感事件。

股东须知

  • 年度报告须结合本更正及新增页面阅读。
  • 公司领导和顾问架构依然坚实,林先生的专业知识可随时为管理层提供。
  • 未有财务、运营或其他实质性重大信息变动。

结论

更正强化了公司年度报告的完整性和透明度,突出创始人持续影响力。投资者应关注林先生的顾问角色,此举虽有助于公司治理信心,但不构成直接价格敏感事件。

免责声明

本文仅供参考,不构成投资建议。投资者应自行调研并咨询专业人士后再做投资决策。


View Chemical Ind Historical chart here



IX Biopharma Extraordinary General Meeting 2026: Share Allotments, Director Awards, and Shareholder Q&A Highlights

iX Biopharma Ltd. EGM Approves Share Issuances and CEO Award...

Ciemas Gold Project Halted: Heavy Rainfall and Power Outages Disrupt Operations

Wilton Resources Faces Operational Challenges at Ciemas Gold...